Abdel-WahabN, ShahM, Suarez-AlmazorME. Adverse events associated with immune checkpoint blockade in patients with cancer: a systematic review of case reports. PLoS One, 2016; 11(7):e0160221.
2.
LopezAT, KhannaT, AntonovN, et al.A review of bullous pemphigoid associated with PD-1 and PD-L1 inhibitors. Int J Dermatol, 2018; 57(6):664–669.
3.
SchmidgenMI, ButschF, Schadmand-FischerS, et al.Pembrolizumab-induced lichen planus pemphigoides in a patient with metastatic melanoma. J Dtsch Dermatol Ges, 2017; 15(7):742–745.
4.
HübnerF, LanganEA, ReckeA. Lichen planus pemphigoides: from lichenoid inflammation to autoantibody-mediated blistering. Front Immunol, 2019; 10:1389.
5.
RzepeckiAK, ChengH, McLellanBN. Cutaneous toxicity as a predictive biomarker for clinical outcome in patients receiving anticancer therapy. J Am Acad Dermatol, 2018; 79(3):545–555.
